专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20080096846A1 Arene Ruthenium (ll) Compounds And Their Use In Cancer Therapy 审中-公开
标题翻译：芳钌（II）化合物及其在癌症治疗中的应用
公开(公告)号：US20080096846A1
公开(公告)日：2008-04-24
申请号：US11660627
申请日：2005-08-19
申请人： Abraha Habtemariam , Peter Sadler
发明人： Abraha Habtemariam , Peter Sadler
IPC分类号： A61K31/28 , A61K31/555 , A61K31/655 , A61P35/00 , C07C245/00 , C07F15/00
CPC分类号： C07C211/65 , C07F17/02
摘要： A ruthenium (II) compound of formula (I): or a solvate on prodrug thereof, wherein: R1, R1, R3, R4, R5 and R6 are independently selected from H, C1-7 alkyl, C5-20 aryl, C3-20 heterocyclyl, halo, ester, amido, acyl, sulfo, sulfonamido, ether, thioether, azo, amino, or R1 and R2 together with the ring to which they are attached form a saturated or unsaturated carbocyclic or heterocyclic group containing up to three 3- to 8-membered carbocyclic or heterocyclic rings, wherein each carbocyclic or heterocyclic ring may be fused to one or more other carbocyclic or heterocyclic rings; X is a neutral or negatively charged N- or S-donor ligand; Y is a counterion; in is 0 or 1; q is 1, 2 or 3; C″ is C1-12 alkylene bound to two A groups; p is 0 or 1 and r is 1 when p is 0 and r is 2 when p is 1; and A and B are each independently O-donor, N-donor or S-donor ligands, and may be connected to one another. The compounds are used in cancer therapy.
摘要翻译：式（I）的钌（II）化合物或其前药上的溶剂化物，其中：R 1，R 1，R 3， R 4，R 5和R 6独立地选自H，C 1-7烷基，C 5-20芳基，C 3-20杂环基，卤素，酯，酰胺基，酰基，磺基，亚磺酰氨基，醚，硫醚，偶氮，氨基或R 1和R 2与它们所连接的环连同形成饱和或不饱和的含有至多三个3-8元碳环或杂环的碳环或杂环基团，其中每个碳环或杂环可以与一个或多个其它碳环或杂环稠合; X是中性或带负电荷的N-或S-供体配体; Y是反抗; in是0或1; q为1,2或3; C“是与两个A基团结合的C 1-12亚烷基; p为0或1，当p为0时r为1，p为1时r为2; A和B各自独立地为O-供体，N-供体或S-供体配体，并且可以彼此连接。这些化合物用于癌症治疗。

2. 发明申请

US20130040925A1 OSMIUM (II) ARENE AZO ANTI-CANCER COMPLEXES 有权
标题翻译： OSMIUM（II）ARENE AZO抗癌复合物
公开(公告)号：US20130040925A1
公开(公告)日：2013-02-14
申请号：US13642729
申请日：2011-04-15
申请人： Ying Fu , Peter John Sadler , Abraha Habtemariam
发明人： Ying Fu , Peter John Sadler , Abraha Habtemariam
IPC分类号： A61K31/555 , A61P35/00 , C07F15/00
CPC分类号： C07F15/002
摘要： The present invention relates to the use of certain osmium containing complexes such as cytotoxic agents particularly for the treatment of cancer. There is also provided novel osmium containing complexes, as well as pharmaceutical formulations comprising such complexes.
摘要翻译：本发明涉及某些含锇复合物如细胞毒剂特别用于治疗癌症的用途。还提供了新颖的含锇络合物，以及包含这种复合物的药物制剂。

3. 发明申请

US20060258634A1 Ruthenium (II) complexes for the treatment of tumors 失效
标题翻译：用于治疗肿瘤的钌（II）复合物
公开(公告)号：US20060258634A1
公开(公告)日：2006-11-16
申请号：US10554271
申请日：2004-04-29
申请人： Abraha Habtemariam , Peter Sadler
发明人： Abraha Habtemariam , Peter Sadler
IPC分类号： A61K31/555 , A61K31/282 , C07F15/00
CPC分类号： C07F17/02
摘要： Ruthenium (II) compounds of formula (I) are useful in the treatment and/or prevention of cancer.
摘要翻译：式（I）的钌（II）化合物可用于治疗和/或预防癌症。

4. 发明授权

US09296772B2 Osmium (II) arene azo anti-cancer complexes 有权
标题翻译：锇（II）芳烃偶氮抗癌复合物
公开(公告)号：US09296772B2
公开(公告)日：2016-03-29
申请号：US13642729
申请日：2011-04-15
申请人： Ying Fu , Peter John Sadler , Abraha Habtemariam
发明人： Ying Fu , Peter John Sadler , Abraha Habtemariam
IPC分类号： C07F15/00 , A61K31/555
CPC分类号： C07F15/002
摘要： The present invention relates to the use of certain osmium containing complexes such as cytotoxic agents particularly for the treatment of cancer. There is also provided novel osmium containing complexes, as well as pharmaceutical formulations comprising such complexes.
摘要翻译：本发明涉及某些含锇复合物如细胞毒剂特别用于治疗癌症的用途。还提供了新颖的含锇络合物，以及包含这种复合物的药物制剂。

5. 发明申请

US20090186864A1 RUTHENIUM (II) COMPOUNDS 审中-公开
标题翻译：（II）化合物
公开(公告)号：US20090186864A1
公开(公告)日：2009-07-23
申请号：US12301373
申请日：2007-05-21
申请人： Abraha Habtemariam , Tijana Bugarcic , Peter John Sadler
发明人： Abraha Habtemariam , Tijana Bugarcic , Peter John Sadler
IPC分类号： A61K31/555 , C07F15/00 , A61P35/00
CPC分类号： C07F17/02
摘要： A ruthenium (II) compound of formula (I): or a solvate form thereof for use in a method of therapy, wherein: R1, R2, R3, R4, R5 and R6 are independently selected from H, C1-7 alkyl, C5-20 aryl, C3-20 heterocyclyl, halo, ester, amido, acyl, sulfo, sulfonamido, ether, thioether, azo and amino, or R1 and R2 together with the ring to which they are attached form a saturated or unsaturated carbocyclic or heterocyclic group containing up to three 3- to 8-membered carbocyclic or heterocyclic rings, wherein each carbocyclic or heterocyclic ring may be fused to one or more other carbocyclic or heterocyclic rings; X is halo or a neutral or negatively charged O, N— or S— donor ligand; Y is a counterion; m is −1, 0, 1 or 2; q is 1, 2 or 3; RC1 and RC2 independently represent one or more optional substituents selected from hydroxy, C1-7 alkoxy, C5-20 aryloxy, C1-7 alkyl, carboxy, C1-7 alkyl ester and C5-20 aryl ester; RN1 and RN2 are independently selected from hydroxy, C1-7 alkoxy, C5-20 aryloxy, C1-7 alkyl, carboxy, C1-7 alkyl ester and C5-20 aryl ester; or RN1 and RN2 together with the pyridine rings to which they are bound form an tricyclic heteraromatic moiety, where the ring formed by RN1 and RN2 together may be optionally substituted by one or more substituents represented by RC3 selected from: hydroxy, C1-7 alkoxy, C5-20 aryloxy, C1-7 alkyl, carboxy, C1-7 alkyl ester and C5-20 aryl ester.
摘要翻译：用于治疗方法的式（I）的钌（II）化合物或其溶剂合物形式，其中：R 1，R 2，R 3，R 4，R 5和R 6独立地选自H，C 1-7烷基，C 5 -20芳基，C3-20杂环基，卤素，酯，酰氨基，酰基，磺基，亚磺酰氨基，醚，硫醚，偶氮和氨基，或R1和R2与它们所连接的环一起形成饱和或不饱和的碳环或杂环其中每个碳环或杂环可以与一个或多个其它碳环或杂环稠合;其中每个碳环或杂环可以与一个或多个其它碳环或杂环稠合; X是卤素或中性或带负电荷的O，N-或S-供体配体; Y是反抗; m为-1,0,1或2; q为1,2或3; RC1和RC2独立地表示选自羟基，C1-7烷氧基，C5-20芳氧基，C1-7烷基，羧基，C1-7烷基酯和C5-20芳基酯中的一个或多个任选的取代基; RN1和RN2独立地选自羟基，C1-7烷氧基，C5-20芳氧基，C1-7烷基，羧基，C1-7烷基酯和C5-20芳基酯; 或RN1和RN2与它们所连接的吡啶环一起形成三环杂芳基部分，其中由RN1和RN2一起形成的环可以任选地被一个或多个选自以下的RC 3所代表的取代基取代：选自：羟基，C 1-7烷氧基，C5-20芳氧基，C1-7烷基，羧基，C1-7烷基酯和C5-20芳基酯。

6. 发明授权

US09408853B2 Iridium/rhodium anti-cancer compounds 有权
标题翻译：铱/铑抗癌化合物
公开(公告)号：US09408853B2
公开(公告)日：2016-08-09
申请号：US13698965
申请日：2011-05-20
申请人： Abraha Habtemariam , Zhe Liu , Joan Josep Soldevila , Ana Maria Pizarro , Peter John Sadler
发明人： Abraha Habtemariam , Zhe Liu , Joan Josep Soldevila , Ana Maria Pizarro , Peter John Sadler
IPC分类号： A61K31/655 , A61K31/555 , A61K31/28 , C07F15/00 , C07F17/02
CPC分类号： A61K31/555 , A61K31/28 , C07F17/02
摘要： The present invention relates to novel iridium and/or rhodium containing complexes for use as a cytotoxic, such as an anti-cancer agent. There is also provided a method of preparing said compounds.
摘要翻译：本发明涉及用作细胞毒性的新型铱和/或铑的络合物，例如抗癌剂。还提供了制备所述化合物的方法。

7. 发明申请

US20100291236A1 OSMIUM COMPOUNDS 审中-公开
标题翻译： OSMIUM化合物
公开(公告)号：US20100291236A1
公开(公告)日：2010-11-18
申请号：US12377051
申请日：2007-08-10
申请人： Peter John Sadler , Anna Frances Acushla Peacock , Sabine Helena Van Rijt , Abraha Habtemariam
发明人： Peter John Sadler , Anna Frances Acushla Peacock , Sabine Helena Van Rijt , Abraha Habtemariam
IPC分类号： A61K31/555 , C07F15/00 , A61K33/24 , A61K31/66 , A61K31/704 , A61K31/7076 , A61P35/00
CPC分类号： C07F17/02
摘要： The present invention relates to osmium compounds of formula (I), their preparation and use in methods of treatment, particularly for cancer treatment.
摘要翻译：本发明涉及式（I）的锇化合物，其在治疗方法中的制备和用途，特别是用于癌症治疗。

8. 发明申请

US20090318402A1 RUTHENIUM (II) COMPOUNDS 审中-公开
标题翻译：（II）化合物
公开(公告)号：US20090318402A1
公开(公告)日：2009-12-24
申请号：US12281801
申请日：2007-03-07
申请人： Sarah Dougan , Abraha Habtemariam , Michael Melchart , Peter John Sadler
发明人： Sarah Dougan , Abraha Habtemariam , Michael Melchart , Peter John Sadler
IPC分类号： A61K31/555 , C07F15/00 , A61P35/00
CPC分类号： C07F17/02 , A61K31/28 , A61K33/24
摘要： A ruthenium (II) compound of formula (I) wherein X is halo or a neutral or negatively charged O, N- or S-donor ligand; Y is a counterion; m is 0 or 1; q is 1, 2 or 3; A is either: (i) (Ru)—NRN1RN2—RN3—(N), where RN1 and RN2 are independently selected from H, optionally substituted C1-7alkyl, C3-20 heterocyclyl and C5-20aryl, and RN3 is C1-2alkylene; or (ii) a nitrogen-containing C5-6aromatic ring, wherein the nitrogen ring atom is bound to the ruthenium atom, and the ring is also bound to the azo-nitrogen, either by a single bond wherein the bond is α or β to the nitrogen ring atom, or by a —CH2− group wherein the bond is x to the nitrogen ring atom; B is optionally substituted C1-7alkyl, C3-20heterocyclyl or C5-20aryl.
摘要翻译：式（I）的钌（II）化合物，其中X为卤素或中性或带负电荷的O，N-或S-给体配体; Y是反抗; m为0或1; q为1,2或3; A是：（i）（Ru）-NRN1RN2-RN3-（N），其中RN1和RN2独立地选自H，任选取代的C 1-7烷基，C 3-20杂环基和C 5-20芳基，并且RN 3是C 1-2亚烷基 ; 或（ii）含氮的C5-6芳环，其中氮环原子与钌原子结合，并且该环也通过单键与偶氮 - 氮结合，其中该键为α或β 氮环原子或通过-CH 2基团，其中键与氮环原子是x; B是任选取代的C 1-7烷基，C 3-20杂环基或C 5-20芳基。

9. 发明申请

US20130065864A1 NOVEL IRIDIUM/RHODIUM ANTI-CANCER COMPOUNDS 有权
标题翻译：新型IRIDIUM / RHODIUM抗癌化合物
公开(公告)号：US20130065864A1
公开(公告)日：2013-03-14
申请号：US13698965
申请日：2011-05-20
申请人： Abraha Habtemariam , Zhe Liu , Joan Josep Soldevila , Ana Maria Pizarro , Peter John Sadler
发明人： Abraha Habtemariam , Zhe Liu , Joan Josep Soldevila , Ana Maria Pizarro , Peter John Sadler
IPC分类号： C07F15/00 , A61P35/02 , A61K31/655 , A61P35/00 , A61K31/555 , A61K31/28
CPC分类号： A61K31/555 , A61K31/28 , C07F17/02
摘要： The present invention relates to novel iridium and/or rhodium containing complexes for use as a cytotoxic, such as an anti-cancer agent. There is also provided a method of preparing said compounds.
摘要翻译：本发明涉及用作细胞毒性的新型铱和/或铑的络合物，例如抗癌剂。还提供了制备所述化合物的方法。

10. 发明授权

US07241913B2 Ruthenium compounds 失效
标题翻译：钌化合物
公开(公告)号：US07241913B2
公开(公告)日：2007-07-10
申请号：US10554271
申请日：2004-04-29
申请人： Abraha Habtemariam , Peter John Sadler
发明人： Abraha Habtemariam , Peter John Sadler
IPC分类号： A61K31/28 , C07F15/00
CPC分类号： C07F17/02
摘要： Ruthenium (II) compounds of formula (I) are useful in the treatment and/or prevention of cancer
摘要翻译：式（I）的钌（II）化合物可用于治疗和/或预防癌症

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式